Apyx Medical Corporation reaffirmed financial guidance for the year ending December 31, 2023. For the period, the company expects total revenue to be in the range of $59.0 million to $62.0 million, representing growth of approximately 33% to 39% year-over-year, compared to total revenue of $44.5 million for the year ended December 31, 2022. Total revenue guidance assumes: Advanced Energy revenue in the range of $51.0 million to $54.0 million, representing growth of approximately 39% to 47% year-over-year, compared to Advanced Energy revenue of $36.8 million for the year ended December 31, 2022.

OEM revenue of approximately $8.0 million, representing growth of approximately 4% year-over-year, compared to $7.7 million for the year ended December 31, 2022. Net loss attributable to stockholders of approximately $10.5 million, compared to $23.2 million for the year ended December 31, 2022.